Saturday 17 October 2026
Export SABS’s income statement to Excel — free account
SAB Biotherapeutics, Inc.
SABS Healthcare Biotechnology
SAB Biotherapeutics, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $1.3 million, down 40.9% from fiscal 2023. In the quarter to June 2026, revenue fell 91.0%, EPS grew 74.3%, free cash flow fell 59.8% and total debt fell 5.01%, each against the same quarter a year earlier.
2.53
0.06
−2.32%
Follow SABS
SAB Biotherapeutics, Inc. (SABS) P/E ratio
SAB Biotherapeutics, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Dec 2024 | 0.0× | — |
| Jun 2024 | 0.0× | — |
| Mar 2024 | 0.0× | — |
| Dec 2023 | 0.0× | — |
| 11 more quarters | Free account |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| FATE Fate Therapeutics, Inc. compare | n/m |
| GLSI Greenwich LifeSciences, Inc. compare | n/m |
| ACIU AC Immune compare | n/m |
| SABS SAB Biotherapeutics, Inc. | n/m |
| LXEO Lexeo Therapeutics, Inc. compare | n/m |
| BBOT BridgeBio Oncology Therapeutics, Inc compare | n/m |
| IMRX Immuneering Corporation compare | n/m |
| SLGL Sol-Gel Technologies Ltd. compare | n/m |
| QTTB Q32 Bio Inc. compare | 2.5× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)